Company intelligence / Profile preview

Scandinavian Gene Synthesis

Västerås, Västmanland County, Sweden

Ownership: Private
Development stage: Other

Overview

Scandinavian Gene Synthesis (SGS DNA), now operating as QIAGEN DNA Synthesis AB, is a Swedish biotechnology company specializing in the custom synthesis of high-purity oligonucleotides, probes, and primers. Founded in 1989 and acquired by QIAGEN in 2012, the company provides critical components for molecular assays, including IVD-grade materials and Locked Nucleic Acid (LNA) modifications. Its products support a wide range of applications in research, diagnostics, and forensic science. The company operates from facilities in Västerås, Sweden, maintaining ISO certifications for quality management and medical device manufacturing.

Modalities: Synthetic oligonucleotide
Industry: Chemicals & Materials

Partnerships

Nanogen

Beyond the preview

Go deeper on Scandinavian Gene Synthesis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Scandinavian Gene Synthesis.

Explore the full profile